Sight Sciences Raises Revenue Guidance Amid Strategic Shifts

Sight Sciences, Inc. ( (SGHT) ) has released its Q3 earnings. Here is a breakdown of the information Sight Sciences, Inc. presented to its investors.

Sight Sciences, Inc. is an eyecare technology company that develops and commercializes innovative interventional technologies aimed at transforming patient care in the ophthalmology sector. The company is known for its minimally invasive solutions targeting prevalent eye diseases such as glaucoma and dry eye disease.

In its third-quarter 2025 earnings report, Sight Sciences announced a slight decrease in total revenue to $19.9 million, a 1% decline from the previous year. Despite this, the company raised its full-year 2025 revenue guidance, reflecting confidence in its strategic direction and operational efficiencies.

The company’s Surgical Glaucoma segment saw a 6% revenue increase, driven by a rise in ordering accounts, while the Dry Eye segment experienced an 88% revenue drop due to a strategic focus on achieving reimbursed market access. Operating expenses were reduced by 11%, and the company reported a net loss of $8.2 million, an improvement from the previous year’s $11.1 million loss. Sight Sciences also appointed new executives to strengthen its leadership team.

Sight Sciences achieved significant milestones in market access and clinical validation, including expanded Medicare coverage for its TearCare procedure and inclusion of its TearCare System in global dry eye guidelines. The company also reported positive clinical outcomes for its OMNI Surgical System in glaucoma treatment.

Looking ahead, Sight Sciences remains optimistic about its growth prospects, supported by strategic initiatives and operational efficiencies. The company aims to maintain momentum in both its glaucoma and dry eye segments while managing expenses and enhancing gross margins.